Analysts expect Cardiovascular Systems Inc (NASDAQ:CSII) to report earnings of ($0.02) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Cardiovascular Systems’ earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at $0.02. Cardiovascular Systems reported earnings per share of $0.01 in the same quarter last year, which would suggest a negative year over year growth rate of 300%. The company is scheduled to report its next quarterly earnings report on Wednesday, May 1st.
On average, analysts expect that Cardiovascular Systems will report full-year earnings of ($0.06) per share for the current fiscal year, with EPS estimates ranging from ($0.13) to $0.02. For the next financial year, analysts forecast that the firm will post earnings of $0.07 per share, with EPS estimates ranging from $0.02 to $0.10. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Cardiovascular Systems.
Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings data on Wednesday, January 30th. The medical device company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.05. Cardiovascular Systems had a net margin of 0.74% and a return on equity of 1.28%. The business had revenue of $60.21 million during the quarter, compared to analysts’ expectations of $59.66 million.
Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. grew its holdings in shares of Cardiovascular Systems by 101.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 122,430 shares of the medical device company’s stock worth $4,793,000 after acquiring an additional 61,572 shares during the period. AQR Capital Management LLC raised its position in Cardiovascular Systems by 45.3% in the third quarter. AQR Capital Management LLC now owns 76,519 shares of the medical device company’s stock valued at $2,995,000 after purchasing an additional 23,864 shares during the period. Teachers Advisors LLC raised its position in Cardiovascular Systems by 420.6% in the third quarter. Teachers Advisors LLC now owns 317,801 shares of the medical device company’s stock valued at $12,439,000 after purchasing an additional 256,759 shares during the period. BlackRock Inc. raised its position in Cardiovascular Systems by 9.3% in the second quarter. BlackRock Inc. now owns 2,479,543 shares of the medical device company’s stock valued at $80,188,000 after purchasing an additional 210,128 shares during the period. Finally, First Quadrant L P CA raised its position in Cardiovascular Systems by 47.9% in the fourth quarter. First Quadrant L P CA now owns 18,475 shares of the medical device company’s stock valued at $526,000 after purchasing an additional 5,981 shares during the period. Institutional investors own 79.66% of the company’s stock.
Cardiovascular Systems stock traded up $1.36 during midday trading on Wednesday, hitting $33.20. The company’s stock had a trading volume of 20,741 shares, compared to its average volume of 236,725. Cardiovascular Systems has a 1-year low of $20.58 and a 1-year high of $40.00. The company has a quick ratio of 3.88, a current ratio of 4.38 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of 653.00 and a beta of 2.09.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
See Also: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.